Carcinome à petites cellules de l’ovaire

Bahri, M.; Lahmar, Rihab; Salah, H. Ben; Kallel, N.; Amar, Mohamed Ben; Daoud, J.

doi:10.1016/j.canrad.2014.01.002

Cited by 7 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SCCO is a rare malignancy and presents many challenges for diagnosis, prediction of outcomes, and overall treatment strategies. [ 6 ] Dickersin et al [ 7 ] first reported 11 cases of SCCOHT in 1982. Eichhorn et al [ 8 ] first proposed the concept of SCCOPT in 1992.…”

Section: Discussionmentioning

confidence: 99%

Primary ovarian small cell carcinoma of pulmonary type with coexisting endometrial carcinoma in a breast cancer patient receiving tamoxifen

Yin

Wei

et al. 2018

Medicine

View full text Add to dashboard Cite

Rationale:Small cell carcinoma of the ovary (SCCO) is a rare and aggressive extra-pulmonary variant of small cell tumors of uncertain histogenesis. The pathogenesis and optimal treatment of SCCO is unclear. We present a very rare case of a synchronous primary ovarian small cell carcinoma and endometrioid adenocarcinoma of the uterus in a patient after 2 years of tamoxifen treatment for breast cancer. This is the first such report in the English literature.Patient concerns:A 46-year-old woman had a history of left breast cancer that was treated with a simple mastectomy and sentinel lymph node biopsy in 2013. The post-operative pathology was invasive ductal carcinoma of the left breast. she had been taking tamoxifen for 2 years. The patient underwent an exploratory laparotomy to reduce the tumor burden, improve bowel compression symptoms, and promote defecation in 2015. The post-operative pathology revealed a rare, simultaneous occurrence of two tumors (endometrial adenocarcinoma and SCCO [pulmonary type]).Diagnoses:Primary ovarian small cell carcinoma of pulmonary type with coexisting endometrial carcinoma in a breast cancer patient.Interventions:The patient received 3 courses of chemotherapy after operation. The effect was not apparent and the general health status was poor.Outcomes:The patient died of progressive disease 7 months post-operatively.Lessons:The present case suggests that tamoxifen use might be among many etiologic factors in SCCO development. Despite its rarity, SCCO requires a high degree of attention in clinical work because it is an aggressive tumor that has a poor prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Primary ovarian small cell carcinoma of pulmonary type with coexisting endometrial carcinoma in a breast cancer patient receiving tamoxifen

Yin

Wei

et al. 2018

Medicine

View full text Add to dashboard Cite

show abstract

“…They are most often revealed by abdominopelvic masses or heaviness. About 66% of patients have hypercalcemia at diagnosis and 2.5% of them have clinical signs of hypercalcemia [ 3 ].…”

Section: Discussionmentioning

confidence: 99%

“…Surgery, chemotherapy, and radiotherapy are the basis of its treatment. Unfortunately, the prognosis remains poor despite the noticeable improvement in the management of these tumors [ 3 , 4 ].…”

Section: Discussionmentioning

confidence: 99%

A rare case of small cell carcinoma of the ovary, hypercalcemic type

Boujida,

Mahdi,

Khmou

et al. 2024

Journal of Surgical Case Reports

View full text Add to dashboard Cite

Small cell carcinoma of ovary, hypercalcemic type (SCCOHT) is an unusual malignant tumor that most commonly affects young women. Unfortunately, it has a very poor prognosis. We describe here an unusual case of a Moroccan young woman with a left ovarian mass and a symptomatic hypercalcemia. Morphologically, there are some malignant tumors that resemble SCCOHT; thus, it is very challenging to diagnose, and immunohistochemistry has a great contribution in it. Hopefully, molecular tools and new therapies will improve the management of these cases in the near future.

show abstract

“…SCCO presents challenges for diagnosis, prediction of outcomes, and overall treatment strategies [1, 2]. Due to limited data, there are no defined treatment protocols [3].…”

Section: Introductionmentioning

confidence: 99%

Genomic alterations in neuroendocrine cancers of the ovary

et al. 2016

View full text Add to dashboard Cite

BackgroundAs we have previously reported, small cell carcinoma of the ovary (SCCO) is a rare, aggressive form of ovarian cancer associated with poor outcomes. In an effort to identify new treatment options, we utilized comprehensive genomic profiling to assess the potential for novel therapies in SCCO.MethodsPatients with SCCO, SCCO-HT (hypercalcemic type), neuroendocrine tumors of the ovary (NET-O), and small cell carcinoma of the lung (SCLC) profiled by Caris Life Sciences between 2007–2015 were identified. Tumors were assessed with up to 21 IHC stains, in situ hybridization of cMET, EGFR, HER2 and PIK3CA, and next-generation sequencing (NGS) as well as Sanger sequencing of selected genes.ResultsForty-six patients with SCCO (10 SCCO, 18 SCCO-HT, 18 NET-O) were identified as well as 58 patients with SCLC for comparison. Patients with SCCO and SCCO-HT were younger (median 42 years [range 12–75] and 26 years [range 8–40], respectively) than patients with NET-O 62 [range 13–76] or SCLC 66 [range 36–86]. SCCO patients were more likely to be metastatic (70 %) than SCCO-HT (50 %) or NET-O (33 %) patients, but at a similar rate to SCLC patients (65 %). PD1 expression varied across tumor type with SCCO (100 %), SCCO-HT (60 %), NET-O (33 %) vs SCLC (42 %). PDL1 expression also varied with SCCO (50 %), SCCO-HT (20 %), NET-O (33 %) and SCLC (0 %). No amplifications were identified in cMET, EGFR, or HER2 and only 1 was found in PIK3CA (NET-O). Actionable mutations were rare with 1 patient with SCCO having a BRCA2 mutation and 1 patient with NET-O having a PIK3CA mutation. No other actionable mutations were identified.ConclusionsNo recurrent actionable mutations or rearrangements were identified using this platform in SCCO. IHC patterns may help guide the use of chemotherapy in these rare tumors.

show abstract

Carcinome à petites cellules de l’ovaire

Cited by 7 publications

References 18 publications

Primary ovarian small cell carcinoma of pulmonary type with coexisting endometrial carcinoma in a breast cancer patient receiving tamoxifen

Primary ovarian small cell carcinoma of pulmonary type with coexisting endometrial carcinoma in a breast cancer patient receiving tamoxifen

A rare case of small cell carcinoma of the ovary, hypercalcemic type

Genomic alterations in neuroendocrine cancers of the ovary

Contact Info

Product

Resources

About